ArticleThe journal of headache and pain2022

Impact of fremanezumab on disability outcomes in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies.

Peter McAllister et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.